Fausto Berti is responsible to set up and lead the Alvotech Clinical Research & Development team, as part of the fully-integrated R&D structure. Thanks to his previous experience, Fausto will be a key resource to help Alvotech become a leading company in biogenerics, through the establishment of an innovative clinical strategy and highly efficient clinical operations.
Fausto brings Alvotech 15 years of experience in Clinical Research. He has been involved in clinical development of biosimilars since 2009, working on different successful programs. Prior to joining Alvotech, Fausto has been a key contributor to the formation of the clinical team at Mylan Biologics, where he was directly involved in all clinical activities for the first wave of biosimilars products.
Prior to working on biosimilars, Fausto had different roles in the management of clinical studies across several therapeutic areas, mainly Oncology, CNS and Autoimmune diseases, both in International Contract Research Organization (PPD and INC Research) and biotech companies (Actelion and BiogenIdec). Fausto holds a Pharm.D. degree and Ph.D. in Pharmacology/Toxicology, both gained at the University of Bologna (Italy). He is a member of the Alvotech Leadership team and he is based in Zurich (Switzerland).